CStone Pharmaceuticals (FRA:PH4) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


FRA:PH4 CStone Pharmaceuticals FRA:PH4
56 GF Score
Price €0.52
GF Value €0.13
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is CStone Pharmaceuticals Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

CStone Pharmaceuticals's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

FRA:PH4 vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, CStone Pharmaceuticals's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CStone Pharmaceuticals Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CStone Pharmaceuticals's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where CStone Pharmaceuticals's Margin of Safety % (DCF Earnings Based) falls into.


FRA:PH4
56GF Score
CStone Pharmaceuticals FRA:PH4
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is CStone Pharmaceuticals (FRA:PH4) Overvalued in 2026?

Based on GuruFocus' analysis, CStone Pharmaceuticals stock appears to be overvalued. The current stock price of €0.52 is trading 301.4% above its estimated GF Value™ of €0.13. GuruFocus considers CStone Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:PH4:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €0.13 vs. price of €0.52 (301.4% above fair value)
  • GF Score™: 56/100 with 7 warning signs

No single metric tells the full story. See the FRA:PH4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CStone Pharmaceuticals Business Description

Address 218 Xinghu Street, C1 Building, North Block, Suzhou Industrial Park, Suzhou, CHN, 215123
CStone Pharmaceuticals is engaged in developing and commercializing immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment. The Group has been operating in one reportable segment, being the research and development of high-complex biopharmaceutical products, the sale of pharmaceutical products, and provide license of its IP or commercialisation licenses to customers.
56GF Score

Get the complete analysis for FRA:PH4

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.52
Price
€0.13
GF Value